A Global Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
Latest Information Update: 16 Jun 2026
At a glance
- Drugs MRNA-3705 (Primary)
- Indications Methylmalonic acidaemia
- Focus Adverse reactions; First in man
- Acronyms Landmark study
- Sponsors Moderna Therapeutics
Most Recent Events
- 16 Jun 2026 Last checked against Clinicaltrials.gov record.
- 06 May 2026 Status changed from active, no longer recruiting to discontinued.
- 02 Sep 2025 According to a Moderna media release, interim result data from this study have been accepted for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM), which will be held September 2-6, 2025 in Kyoto, Japan, at the Kyoto International Conference Center.